GRI

GRI Bio Inc.

GRI.US gribio.com + Research + Basket
CIK 0001824293
Employees 3
Phone 619 400 1170
Fiscal year end December
IPO Feb 10, 2021
Address 2223 Avenida de la Playa, La Jolla, CA, United States, 92037
1.43
-0.11 (-7.14%)
USD · NASDAQ
52-week range
1.36
64.12
Trading at 0% of the 52-week range
Market Cap
3.37M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
4.70
Div. Yield
N/A
% Institutions
4.28%
% Insiders
0.375%

1 Year

-96.9%

3 Year

-100.0%

10 Year

-100.0%
Description

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Actions

Add an action for GRI.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. W. Marc Hertz Ph.D. Co-Founder, CEO, President & Director 1970
Dr. Vipin Kumar Chaturvedi Ph.D. Co-Founder & Chief Scientific Officer 1959
Ms. Leanne M. Kelly CFO & Corporate Secretary 1977
Dr. Albert Agro Ph.D. Co-Founder & Chief Medical Officer 1964

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
HRT FINANCIAL LLC 28.78K Jun 30, 2026 1.32% $0.00 0.00%
Vanguard Capital Management, LLC 21.37K Jun 30, 2026 0.98% $0.00 0.00%
Geode Capital Management, LLC 13.87K Jun 30, 2026 0.63% $0.00 -24.78%
Citadel Advisors Llc 13.38K Jun 30, 2026 0.61% $0.00 0.00%
Morgan Stanley - Brokerage Accounts 8.74K Jun 30, 2026 0.40% $0.00 0.00%
UBS Group AG 4.92K Jun 30, 2026 0.23% $0.00 -43.59%
Tower Research Capital LLC 2.43K Jun 30, 2026 0.11% $0.00 129.62%
Barclays PLC 83.00 Jun 30, 2026 0.00% $0.00 0.00%
BlackRock Inc 7.00 Jun 30, 2026 0.00% $0.00 0.00%
Danske Bank A/S. 2.00 Jun 30, 2026 0.00% $0.00 0.00%
Caitong International Asset Management Co., Limited. 2.00 Jun 30, 2026 0.00% $0.00 0.00%
SBI Securities Co Ltd 0.00 Jun 30, 2026 0.00% $0.00 -100.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Extended Market Index 9.17K 0.42% ▲ 0.00% Aug 31, 2026
2 Fidelity Series Total Market Index 872.00 0.04% ▲ 0.00% Aug 31, 2026

Financial Highlights

▼
Market Cap: $3.37M
EBITDA: $-9.68M
Book Value: $4.70
Earnings/Share: $-14.71
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -70.93%
ROE (TTM): -142.02%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $-7.60M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 2.19M
Shares Float: 2.19M
% Insiders: 0.375%
% Institutions: 4.28%
Shares Short: 66.12K
Shares Short (Prior Month): 69.43K
Short Ratio: 0.93
Short % Float: 3.02%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-4.00K
Gross Profit
subtotal
$-4.00K
SG&A
adjust
$-5.16M
R&D
adjust
$-6.82M
Operating Income
subtotal
$-11.98M
Other / Non-Operating Items
adjust
$21.00K
Net Income
subtotal
$-11.96M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about GRI.US!